ClearPoint Neuro (NASDAQ:CLPT) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

ClearPoint Neuro (NASDAQ:CLPT) had its price objective lifted by research analysts at Stifel Nicolaus from $19.00 to $25.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 90.99% from the company’s previous close.

CLPT has been the topic of a number of other reports. Lake Street Capital upped their target price on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, January 21st. B. Riley raised their target price on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th.

ClearPoint Neuro Price Performance

Shares of NASDAQ CLPT opened at $13.09 on Tuesday. The firm’s 50-day moving average is $15.47 and its two-hundred day moving average is $14.04. The company has a market capitalization of $361.70 million, a PE ratio of -18.97 and a beta of 1.06. ClearPoint Neuro has a 12-month low of $5.11 and a 12-month high of $19.22.

ClearPoint Neuro (NASDAQ:CLPT) last announced its earnings results on Wednesday, February 26th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The company had revenue of $7.77 million for the quarter, compared to analyst estimates of $8.23 million. On average, analysts forecast that ClearPoint Neuro will post -0.66 EPS for the current fiscal year.

Institutional Trading of ClearPoint Neuro

A number of hedge funds have recently added to or reduced their stakes in the business. R Squared Ltd purchased a new position in shares of ClearPoint Neuro during the 4th quarter worth about $32,000. Barclays PLC raised its stake in ClearPoint Neuro by 24.3% during the third quarter. Barclays PLC now owns 5,674 shares of the company’s stock worth $64,000 after purchasing an additional 1,109 shares during the period. AlphaQuest LLC acquired a new position in shares of ClearPoint Neuro in the 4th quarter valued at $80,000. Tower Research Capital LLC TRC purchased a new stake in shares of ClearPoint Neuro during the 4th quarter valued at $93,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of ClearPoint Neuro by 58.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company’s stock worth $110,000 after buying an additional 3,612 shares during the last quarter. 30.08% of the stock is owned by institutional investors and hedge funds.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.